The new venture called Galvani Bioelectronics will develop implants to treat disorders including arthritis, asthma, and diabetes.
Google’s life sciences unit Verily is partnering up with British pharmaceutical giant GlaxoSmithKline for a spinout venture focused on bioelectronic devices. Bioelectronic medicine is a new scientific discipline that seeks to treat a number of chronic diseases including diabetes, asthma, arthritis, and inflammatory bowel disease by using miniature devices implanted in the body that are able to modify the electrical signals of nerves in the body.
